Nuvation Pharma (NUVB) Net earnings per share growth forecast for next year

Corporate company logo of Nuvation Bio Inc. (NUVB)

Nuvation Bio Inc. (NUVB) attracts top researchers through its scientific culture and stock options. The projected one-year forward growth in net income per share confirms this potential, with the 31.90 metric serving as the target level. Business stability relies on US centers and new drugs, while current success depends on management's integration of acquired assets.

Nuvation Pharma (NUVB): Net earnings per share growth forecast for next year from 07/04/2022 to 11/16/2026

Summary analytical data breakdowns for Nuvation Pharma (NUVB)

- share price and consensus valuation forecast:
Fundamental company analysis:Nuvation Bio Inc.
Finished products of Nuvation Bio Inc

Professional managers utilize fundamental metrics to filter assets, assessing return potential through analyst consensus forecasts for net earnings per share growth rates. This indicator measures expected EPS dynamics, which in the case of Nuvation Bio Inc. (NUVB) reflects the commercialization of late-stage oncology developments and patent protection, determining investment attractiveness via the valuation of next year's EPS growth.

Competitor analysis for Nuvation Bio Inc.

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Day One Biopharmaceuticals Inc (DAWN)|MNPR - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Inhibrx Biosciences Inc INBX|I-Mab - Net earnings per share growth forecast for next year|FENC - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year herontx.com|NVCT: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Coherus CHRS|Expected earnings per share growth for next year CRBP|Expected net earnings per share growth next year Cardiff Oncology CRDF|Expected earnings per share growth for next year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Expected earnings per share trend next year|Lixte Biotechnology - Expected earnings per share growth for next year|Projected earnings per share increase next year CTXR (Citius Pharma)|Cellectar - Earnings growth forecast for next year|Expected earnings per share trend next year BLRX (BioLineRx Corp)|CANF: Earnings growth forecast for next year|Expected net earnings per share growth next year Aprea (APRE)|Net earnings per share growth forecast for next year kaziatherapeutics.com|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)